Patent classifications
C12N2720/12232
GENERATION OF ANTIBODIES TO TUMOR ANTIGENS AND GENERATION OF TUMOR SPECIFIC COMPLEMENT DEPENDENT CYTOTOXICITY BY ADMINISTRATION OF ONCOLYTIC VACCINIA VIRUS
The present invention relates to methods and compositions for use in inducing tumor-specific antibody mediated complement-dependent cytotoxic response in an animal having a tumor comprising administering to said animal a composition comprising a replication competent oncolytic virus wherein administration of the composition induces in the animal production of antibodies that mediate a CDC response specific to said tumor.
Generation of antibodies to tumor antigens and generation of tumor specific complement dependent cytotoxicity by administration of oncolytic vaccinia virus
The present invention relates to methods and compositions for use in inducing tumor-specific antibody mediated complement-dependent cytotoxic response in an animal having a tumor comprising administering to said animal a composition comprising a replication competent oncolytic virus wherein administration of the composition induces in the animal production of antibodies that mediate a CDC response specific to said tumor.
Liquid viral formulations
Provided herein are liquid viral formulations useful for the stabilization and storage of viruses and methods of preparing these formulations. The liquid viral formulations described herein include a virus (e.g., a purified virus) and a non-viral composition including excipients and a liquid carrier. The formulations can be used, for example, to retain the infectivity or immunogenicity of viruses during periods of storage.
ATTENUATED REOVIRUS
Compositions and methods are provided that relate to an attenuated reovirus exhibiting oncolytic activity toward cancer cells while displaying reduced lytic activity toward non-malignant cells. Exemplified is an attenuated human reovirus derived from persistently infected fibrosarcoma cells that lacks wild-type reovirus S1 and S4 genes and consequently lacks a detectable reoviral outer capsid .sigma.1 protein and expresses a mutated reoviral outer capsid .sigma.3 protein.
Oncolytic reovirus
The present disclosure provides modified reovirus with improved characteristics, including improved oncolytic activity. Reoviruses provided herein include resortant viruses as well as viruses expressing mutated proteins. Methods of using such modified reovirus for inducing cancer cell lysis as well as treatment of cancer are disclosed. Also provided are methods tailored for induction of a desired cytokine profile in conjunction with, e.g., methods of inducing cancer cell oncolysis.